ArticleCureus2025
Primary Pulmonary Epithelioid Angiosarcoma With Partial Response to Paclitaxel Treatment: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epithelioid Angiosarcoma Presenting With Bilateral Hemothorax and Hemoptysis: A Case Report.Case reports in pulmonology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary epithelioid angiosarcoma is a rare, highly aggressive malignancy for which established treatment protocols are lacking. Here, we report the case of a 73-year-old male diagnosed with primary pulmonary epithelioid angiosarcoma with multiple metastases. While paclitaxel is effective for angiosarcoma, its use in pulmonary epithelioid angiosarcoma, to our knowledge, has not been previously reported. Surgery and radiotherapy were not feasible in this patient due to the advanced disease stage. Although disease progression ultimately occurred, weekly paclitaxel monotherapy achieved a clinically meaningful partial response. This case highlights that paclitaxel monotherapy selected based on the patient's overall condition can be a rational therapeutic choice to achieve objective tumor control in frail patients, serving as a valuable benchmark for individualized treatment selection in the absence of a standard treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.